Diffusion Pharmaceuticals Inc (DFFN) |
|
1.02 -0.04 (-3.77%)
|
03-03 16:19 |
|
Open: |
1.04 |
Pre. Close: |
1.06 |
|
High:
|
1.065 |
Low:
|
1 |
|
Volume:
|
5,955,761 |
Market Cap:
|
104M |
|
|
|
|
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. The company is headquartered in Charlottesville, Virginia and currently employs 10 full-time employees. The firm is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The firm's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The firm's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.101 - 1.108 |
1.108 - 1.113 |
|
Low:
|
1.034 - 1.042 |
1.042 - 1.048 |
|
Close:
|
1.049 - 1.061 |
1.061 - 1.07 |
|
Technical analysis |
as of: 2021-03-03 4:02:37 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.76 One year: 2.16 |
| Support: |
Support1: 0.96 Support2: 0.80 |
| Resistance: |
Resistance1: 1.51 Resistance2: 1.85 |
| Pivot: |
1.25 |
| Moving Average: |
MA(5): 1.07 MA(20): 1.27
MA(100): 0.95  MA(250): 0.88 |
| MACD: |
MACD(12,26): -0.02 Signal(9): 0.03 |
| Stochastic oscillator: |
%K(14,3): 11.61 %D(3): 14.48 |
| RSI: |
RSI(14): 42.81 |
| 52-week: |
High: 1.85 Low: 0.25 Change(%): 155.0 |
| Average Vol(K): |
3-Month: 755229 10-Days: 915097 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.DFFN has closed above bottom band by 18.6%. Bollinger Bands are 137.1% wider than normal. The large width of the bands suggest high volatility as compared to DFFN's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 26 Feb 2021
Diffusion Pharmaceuticals Inc. - Consensus Indicates Potential 137.1% Upside - DirectorsTalk Interviews
Tue, 23 Feb 2021
Will Diffusion Pharmaceuticals Inc (DFFN) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Fri, 19 Feb 2021
Is Diffusion Pharmaceuticals Inc (DFFN) a Good Choice in Biotechnology Friday? - InvestorsObserver
Thu, 18 Feb 2021
Is Diffusion Pharmaceuticals Inc (DFFN) Stock a Great Value? - InvestorsObserver
Thu, 18 Feb 2021
Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock - Yahoo Finance
Wed, 17 Feb 2021
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
64 |
| Shares Float (M) |
64 |
|
% Held by Insiders
|
0.21 |
|
% Held by Institutions
|
10.71 |
|
Shares Short (K)
|
722 |
|
Shares Short P. Month (K)
|
897 |
Stock Financials |
|
EPS
|
-0.383 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.450 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-38.6 |
|
Return on Equity (ttm)
|
-65.7 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.230 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-13 |
|
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
|
PE Ratio
|
-2.66 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.27 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-5.18 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
